These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18035730)

  • 1. [Multicentre study of comparative efficacy of meropenem and combined regimens for empirical antibacterial therapy of severe nosocomial infections: results of clinical and pharmacoeconomic analysis].
    Iakovlev SV; Beloborodov VB; Sidorenko SV; Iakovlev VP; Grigor'ev KB; Eliseeva EV; Kon EM; Levit AL; Kostina GV; Kuprenkov AV; Mukhacheva SIu; Saturnov AV; Sergeev IN; Spasov GP; Stakanov AV; Ushakova MA
    Antibiot Khimioter; 2006; 51(7):15-27. PubMed ID: 18035730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia.
    Siempos II; Vardakas KZ; Manta KG; Falagas ME
    Eur Respir J; 2007 Mar; 29(3):548-60. PubMed ID: 17329491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
    Garau J; Blanquer J; Cobo L; Corcia S; Daguerre M; de Latorre FJ; León C; Del Nogal F; Net A; Rello J
    Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):789-96. PubMed ID: 9447899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group.
    Krumpe PE; Cohn S; Garreltes J; Ramirez J; Coulter H; Haverstock D; Echols R
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():117-28. PubMed ID: 10225582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Multicenter open randomized trial of meropenem in comparison to ceftazidime and amikacin used in combination in severe hospital infections].
    Iakovlev SV; Iakovlev VP; Derevianko II; Kira EF;
    Antibiot Khimioter; 1998; 43(1):15-23. PubMed ID: 9532327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia.
    Caldwell JW; Singh S; Johnson RH
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():129-34. PubMed ID: 10225583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia.
    Scaglione F; Esposito S; Leone S; Lucini V; Pannacci M; Ma L; Drusano GL
    Eur Respir J; 2009 Aug; 34(2):394-400. PubMed ID: 19213786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative study of the cost-/effectiveness relationship of initial therapy with imipenem/cilastatin in nosocomial pneumonia. Group study].
    Rodloff AC; Laubenthal HJ; Bastian A; Bestehorn K; Büchele G; Gaus W
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 Apr; 31(3):172-80. PubMed ID: 8672620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.
    Joseph J; Rodvold KA
    Expert Opin Pharmacother; 2008 Mar; 9(4):561-75. PubMed ID: 18312158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative activity of meropenem and other antibiotics against the pathogens of nosocomial infections].
    Sidorenko SV; Rezvan SP; Grudinina SA; Sterkhova GV; Aleksandrova IA
    Antibiot Khimioter; 1998; 43(1):4-14. PubMed ID: 9532326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evidence-based medicine, health costs and treatment of intra-abdominal infection].
    Badía X; Brosa M; Tellado JM
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():86-94. PubMed ID: 10605193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Obtain best usage of meropenem dose in severe infections. Results of an observational multicenter study].
    Alvarez-Sánchez B; Alvarez-Lerma F; Romero J; Fernández L; Ruiz F; Sancho H
    Rev Esp Quimioter; 2008 Sep; 21(3):143-8. PubMed ID: 18792813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
    Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
    Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections.
    Huizinga WK; Warren BL; Baker LW; Valleur P; Pezet DM; Hoogkamp-Korstanjep JA; Karran SJ
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():179-89. PubMed ID: 8543493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of three antimicrobial drugs protocol (Ceftriaxone, Gentamicin/Amikacin and Metronidazole) versus two antimicrobial drugs protocol (Ceftriaxone and Metronidazole) in cases of intra-abdominal sepsis.
    Khan S; Gupta DK; Khan DN
    Kathmandu Univ Med J (KUMJ); 2005; 3(1):55-63. PubMed ID: 16401946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.
    Brunkhorst FM; Oppert M; Marx G; Bloos F; Ludewig K; Putensen C; Nierhaus A; Jaschinski U; Meier-Hellmann A; Weyland A; Gründling M; Moerer O; Riessen R; Seibel A; Ragaller M; Büchler MW; John S; Bach F; Spies C; Reill L; Fritz H; Kiehntopf M; Kuhnt E; Bogatsch H; Engel C; Loeffler M; Kollef MH; Reinhart K; Welte T;
    JAMA; 2012 Jun; 307(22):2390-9. PubMed ID: 22692171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
    Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ
    Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
    Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meropenem: a review of its use in patients in intensive care.
    Hurst M; Lamb HM
    Drugs; 2000 Mar; 59(3):653-80. PubMed ID: 10776838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current guidelines for the treatment of severe pneumonia and sepsis.
    Bodmann KF
    Chemotherapy; 2005 Aug; 51(5):227-33. PubMed ID: 16103664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.